{"disease":{"id":"treatment-prior-to-tumor-specific-t-cell-infusion-therapy","name":"Treatment prior to tumor-specific T-cell infusion therapy","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":7,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"cyclophosphamide","indication_name":"Treatment prior to tumor-specific T-cell infusion therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytoxan (Lyophilized)","generic_name":"cyclophosphamide","company_name":"Baxter","drug_phase":"marketed","molecular_target":"Tumor cell DNA","drug_class":"Alkylating agent","quality_score":10,"revenue":"1000.0","mechanism":"Cyclophosphamide cross-links tumor cell DNA and interferes with malignant cell growth through active alkylating metabolites."},{"drug_id":"bendamustine","indication_name":"Treatment prior to tumor-specific T-cell infusion therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Treanda","generic_name":"BENDAMUSTINE","company_name":"Baxter","drug_phase":"marketed","molecular_target":"Histone deacetylase 6","drug_class":"Alkylating Drug","quality_score":63,"revenue":null,"mechanism":"Treanda works by attaching an alkyl group to the DNA of cancer cells, interfering with their ability to replicate and grow."},{"drug_id":"cyclophosphamid","indication_name":"Treatment prior to tumor-specific T-cell infusion therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cyclophosphamid","company_name":"Zhejiang University","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"etoposide","indication_name":"Treatment prior to tumor-specific T-cell infusion therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vepesid","generic_name":"etoposide","company_name":"Bristol-Myers Squibb K.K.","drug_phase":"marketed","molecular_target":"DNA topoisomerase 2-alpha","drug_class":"Topoisomerase Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"chembl-chembl1200796","indication_name":"Treatment prior to tumor-specific T-cell infusion therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytoxan (Lyophilized)","generic_name":"CYCLOPHOSPHAMIDE","company_name":"Baxter","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"cyclophosphamide","quality_score":10,"revenue":null,"mechanism":"Cytoxan works by interfering with the DNA replication process in rapidly dividing cancer cells."},{"drug_id":"bendamustin","indication_name":"Treatment prior to tumor-specific T-cell infusion therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Bendamustin","company_name":"Meir Medical Center","drug_phase":"marketed","molecular_target":"Histone deacetylase 1, Histone deacetylase 10, Histone deacetylase 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"etoposid","indication_name":"Treatment prior to tumor-specific T-cell infusion therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Etoposid","company_name":"University of Ulm","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, Canalicular multispecific organic anion transporter 2, Multidrug resistance-associated protein 6","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":7,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}